AstraZeneca Plc (STO: AZN) reported on Tuesday that as of 31 December 2017, the issued share capital of the company with voting rights was 1,266,221,605 ordinary shares of USD0.25.
Also, no shares are held in treasury. Therefore, the total number of voting rights in AstraZeneca Plc was 1,266,221,605.
According to the company this figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca Plc under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
AstraZeneca is a science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular & Metabolic Diseases and Respiratory. It is also selectively active in the areas of autoimmunity, neuroscience and infection.
GAIA and Daiichi Sankyo Europe partner on digital therapeutic for cardiovascular care
Esperion to acquire Corstasis, expanding cardiovascular portfolio
Circio reports up to 50-fold gene expression gain in eye for circVec-AAV platform
Celyad Oncology sells C-Cathez catheter to CellProthera
Realheart secures European patent for artificial heart technology
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Myqorzo and Redemplo receive regulatory approval in China
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator